



## **GNI Researchers in China Identify Important New Regulator of Inflammation**

**Tokyo, October 17, 2007** – GNI Ltd (TSE Mothers Code: 2160), a leading biopharmaceutical company in Japan and China, announced today that researchers at its China based affiliate Shanghai Genomics have identified an important new regulator of inflammation. The findings of this research will be published by *Biochimica et Biophysica Acta (BBA)* (Issue 11, November, 2007). The article is also available online at <http://dx.doi.org/10.1016/j.bbagen.2007.07.010>

The TNF-NF- $\kappa$ B signaling pathway plays a key role in the regulation of inflammation, immune responses and programmed cell death. Abnormal activation of NF- $\kappa$ B leads to many inflammatory and autoimmune diseases in humans. Pharmaceutical companies have, for a long time, targeted components of the TNF-NF- $\kappa$ B signaling pathway to design drugs against these immunological disorders. The identification of a new activator of NF- $\kappa$ B provides GNI researchers with another potential drug target to develop novel therapeutic interventions for treating certain kinds of human inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Dr. Jun Wu, the co-author of the article and Chief Scientific Officer of GNI and Shanghai Genomics, said, "This publication, together with our previous publications in PNAS and other scientific journals, demonstrates that we have built a platform capable of integrated drug target discovery. We will continue to expand our product pipeline through both in-house and collaborative research."

### **For further inquiries**

Tetsuya Yoshikawa                      Tel: +81 (03) 3580-0751  
Ying Luo                                      Tel: +86 1381-769-8961

### **Notes to editors**

#### **About GNI**

Founded in 2001, GNI is a clinical-stage international drug development company with headquarter in Japan and major operation China. GNI has successfully mapped gene regulatory networks via a complex process of reverse-engineering. Furthermore, GNI has developed the technology required to apply this data to drug development and discovery. In June 2005, GNI acquired Shanghai Genomics, which operates an integrated drug discovery and development platform in Shanghai, China. The combined strength of GNI and Shanghai Genomics has resulted in research collaboration with major international pharmaceutical companies. For further information, please visit [www.gene-networks.com](http://www.gene-networks.com) and [www.shanghai-genomics.com](http://www.shanghai-genomics.com).

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "could," "may," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.